As the number of FDA-approved biosimilar products continues to grow, the need for a solid guiding
framework becomes more critical than ever before. While the stakeholders wait for finality on the rules
governing significant matters like interchangeability, substitution and equivalency, it is clear that
biosimilars will remain a top priority for the FDA.
Hosted by ACI, 14th Summit on Biosimilars & Innovator Biologics returns for another exciting year with curated programming that will provide the critical updates you need to prepare for the considerable changes that will take place in the next year around the scope of products that are regulated and litigated.
This year’s chairs include James T. Evans, Ph.D. (Senior Director, Assistant General Counsel, Dispute
Resolution at Regeneron Pharmaceuticals), Henry Gu (SVP, Head of IP at Zentalis Pharmaceuticals) and Cory Wohlbach (Global Vice President at Biosimilar Regulatory Affairs, Teva Pharmaceuticals), and they will be joined by a highly respected faculty of speakers.
The 14th Summit on Biosimilars & Innovator Biologics takes place on June 27 – 28, 2023 in Boston, MA.
Visit http://bit.ly/3mTURNX to view this year’s agenda and learn more.
Save 10% with the PM360 promo code: D10-999-PM360
Online: http://bit.ly/3mTURNX
Email: customerservice@americanconference.com
Phone: 1-888-224-2480